According to the specific situation, patients can choose to continue treatment with dosage of ectinib, replace it with other targeted drugs, replace it with chemotherapy and other methods.
1. Continue treatment with dosage: Ectinib is suitable for non-small cell lung cancer patients with sensitive mutation of EGFR gene, if slow secondary resistance occurs in the process of using Ectinib, dosage can be considered to continue the treatment, and some patients with slow progression can benefit from dosage treatment.
2. Replacement with other targeted drugs: after resistance to ectinib, genetic testing can be improved again, and if secondary T790M mutation occurs, it can be replaced by oxitinib for treatment.
3. Replacement with chemotherapy: some patients using ectinib have rapid drug resistance and rapid disease progression, and if no new mutation is found in the genetic test again, they can consider replacing it with chemotherapy to control the disease.
Therefore, different treatments can be chosen according to the situation after resistance to Ectinib. It is suggested that patients should find and analyze the reasons for drug resistance under the guidance of doctors and choose the treatment method suitable for them.